{
    "nctId": "NCT01372618",
    "briefTitle": "Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor",
    "officialTitle": "Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor",
    "overallStatus": "TERMINATED",
    "conditions": "Ductal Carcinoma in Situ",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 9,
    "primaryOutcomeMeasure": "Cell Proliferation and Apoptosis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 21 years of age and older\n* Must sign informed consent, witnessed, and dated prior to entry\n* The participant has breast biopsy consistent with Ductal Carcinoma in situ (DCIS)\n* Performance Status: ECOG 0-1 unless mobility is limited from chronic physical handicap\n* No clinical evidence of other malignancies (except Basal Cell carcinoma)\n* Complete blood count, differential and platelet count must be WNL or verified by the study chair to be related to conditions not interfering with normal health status\n* Adequate hepatic and renal function (these must be WNL or verified by study chair to be related to conditions not interfering with normal health status)\n* Normal fasting glucose\n* No history of diabetes\n* Medically and Psychologically able to comply with all study requirements\n* Accessible for Follow up\n\nExclusion Criteria:\n\n* Less than 21 years of age\n* Known invasive breast cancer of any type\n* Bilateral prophylactic mastectomy\n* Prior malignancy of any type that occurred less than 5 years previously, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\n* Existing non-malignant disease that would preclude the administration of pasireotide\n* Pregnancy: All subjects will have a beta-hCG serum pregnancy test to rule out pregnancy, a history will also be taken to make certain that recent sexual exposure does not put them at risk for pregnancy. If so a second serum pregnancy test will be done. Volunteers will be asked to use barrier contraception during study.\n* Tamoxifen or other preventive measures within 6 months\n* Serious Psychiatric condition or addictive disorder\n* Diabetes or elevated fasting blood sugar either by history or by HgbA1c greater than 6.5% or fasting serum glucose greater than 100mg/dL on screening labs. If fasting serum glucose is greater than 100mg/dL on screening labs, this test will be repeated to confirm the results\n* Inability to inject medication or test for finger stick glucose\n* Gall bladder disease\n* History of cholecystitis without cholecystectomy\n* Electrolyte abnormalities (particularly hypokalemia or hypomagnesemia)\n* Contraindication for MRI\n* If tumor size is \\< 1cm on mammography and all calcifications are removed on core biopsy the patient will be excluded.\n\nQT related exclusion criteria\n\n* QTcF at screening \\> 450 msec.\n* History of syncope or family history of idiopathic sudden death.\n* Sustained or clinically significant cardiac arrhythmias.\n* Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block.\n* Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure\n* Concomitant medication(s) known to increase the QT interval.\n\nHepatic Related Exclusion Criteria\n\n* Baseline Alanine transaminase (ALT) or Aspartate transaminase (AST) \\> 2x upper limit of normal (ULN) without known complications of metastatic liver disease or primary hepatic disease (e.g. Cushing's disease and Acromegaly studies).\n* Baseline Total Bilirubin \\> 1.5x ULN",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}